bromantane vs Noopept (omberacetam; GVS-111)

bromantane (B-tier) vs Noopept (omberacetam; GVS-111) (B-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

bromantane · tier B

a Russian antiasthenic CNS drug with older human studies in illness-related fatigue, incomplete modern replication, no traceable primary human half-life source, and in-competition WADA prohibition.

bromantane has a real Russian drug and human-study record for asthenia, but that record does not establish healthy cognitive enhancement, long-term safety, or the internet's preferred half-life number.

728 patients in the largest indexed Russian asthenia study · half-life not structured; the repeated 11.21-hour human claim was not traced to an accessible primary PK source · focus

Noopept (omberacetam; GVS-111) · tier B

omberacetam, a small-molecule cognitive drug sold as a registered 10 mg oral tablet in Russia. the cited human signal comes from one small patient comparison, not a healthy-user trial.

Noopept has a current Russian drug registration and a limited patient signal. It does not have placebo-controlled evidence of cognitive enhancement in healthy people, and sampled US supplements did not reliably define the exposure.

53 patients enrolled in the main active-comparator study · half-life 22.05 plus or minus 14.37 minutes in a sparsely reported human conference abstract · focus

at a glance

• bromantane: tier B · 728 patients in the largest indexed Russian asthenia study
• Noopept (omberacetam; GVS-111): tier B · 53 patients enrolled in the main active-comparator study

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.